The islets of Langerhans are tiny clusters of hormone-producing cells scattered throughout the pancreas, and they serve as the body’s primary blood-sugar control system. Each islet contains several cell types that release different hormones, with insulin-secreting beta cells and glucagon-secreting alpha cells doing the heaviest lifting. But the islets are far more than simple sugar sensors. Their cells talk to each other through local chemical signals, respond to cues from the gut and nervous system, and even follow a built-in circadian clock that adjusts hormone output depending on the time of day.
What the Islets Actually Look Like
If you learned about islets from a textbook, you probably saw a tidy diagram: a core of beta cells wrapped in a shell of alpha and delta cells, like an M&M with a clean coating. That picture comes from studies of mouse islets, and it turns out humans do things differently. Confocal microscopy of human pancreatic tissue shows that insulin-producing beta cells, glucagon-producing alpha cells, and somatostatin-producing delta cells are scattered throughout the islet with no obvious layering or anatomical subdivisions.1PubMed Central. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function Most beta cells in human islets sit right next to other endocrine cell types, lined up along blood vessels in no particular order. That arrangement means the chemical conversations between neighboring cells are more varied and less predictable than the neat mouse model suggests.
Human islets also differ in their cell ratios. Compared with mouse islets, human islets contain proportionally fewer beta cells and more alpha cells.1PubMed Central. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function The blood supply differs as well: human islets have roughly five-fold fewer blood vessels per unit area than mouse islets.2PubMed Central. Human Islets Have Fewer Blood Vessels than Mouse Islets and the Density of Islet Vascular Structures Is Increased in Type 2 Diabetes These structural differences matter for researchers because much of what we “know” about islet function was first worked out in rodents. Translating those findings to humans requires care, because the physical layout of the cells and the blood flow around them shapes how hormones get released and where they travel first.
The Major Hormones and the Cells That Make Them
Each islet is a miniature endocrine organ housing at least four distinct cell types, each producing a different hormone with a different job.
- Beta cells: The most abundant endocrine cell in the islet, responsible for secreting insulin. Insulin lowers blood sugar by signaling tissues to take up glucose.
- Alpha cells: Produce glucagon, which raises blood sugar by prompting the liver to release stored glucose. Alpha cells are especially important between meals and during exercise.
- Delta cells: Secrete somatostatin, a hormone that acts locally to dial down both insulin and glucagon secretion, functioning as a kind of volume knob for the islet’s output.3PubMed Central. Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function
- Epsilon cells: A small population that releases ghrelin, which suppresses insulin release from beta cells and also plays a role in beta-cell growth and survival.4PubMed Central. Development and Characteristics of Pancreatic Epsilon Cells
There are also PP cells (sometimes called F cells) that produce pancreatic polypeptide, a hormone involved in appetite and digestive regulation. PP cells tend to concentrate in the head of the pancreas and play a subtler role than the other four types.
How Beta Cells Sense Glucose and Release Insulin
The beta cell’s response to rising blood sugar is one of the most tightly choreographed processes in the body. When glucose enters a beta cell, it gets broken down through a chain of metabolic steps. As those steps proceed, the cell produces more ATP, and the ratio of ATP to ADP rises sharply.5PubMed Central. A pathway model of glucose-stimulated insulin secretion in the pancreatic β-cell That shift in energy balance closes a specific type of potassium channel on the cell’s surface, which changes the cell’s electrical charge, opens calcium channels, and triggers insulin-filled packets to fuse with the cell membrane and spill their contents into the bloodstream.
The whole sequence is glucose-dependent, which is the key safety feature. At low blood sugar, the ATP-to-ADP ratio stays low, the potassium channels stay open, and insulin stays put. The system ensures that insulin only comes out in meaningful quantities when there is actually excess glucose to deal with. This is also why diabetes researchers care so much about the metabolic health of beta cells: if any step in the chain is compromised, the entire secretion process can falter.
Alpha Cells and the Glucagon Puzzle
Glucagon’s job is conceptually simple: raise blood sugar when it drops too low. But how alpha cells know when to secrete glucagon and when to stop is surprisingly contentious. Two broad ideas compete. One holds that alpha cells have their own internal glucose-sensing machinery and reduce glucagon output as glucose rises. The other says that alpha cells are controlled mainly by signals from their neighbors, especially the inhibitory effects of insulin from nearby beta cells and somatostatin from delta cells.
Mathematical modeling suggests that both mechanisms likely operate at the same time, and that the balance between them shifts under different conditions.6PubMed Central. Glucagon secretion from pancreatic α-cells The same modeling work points to a provocative explanation for the glucagon problems seen in diabetes: abnormally high somatostatin activity could suppress glucagon when blood sugar is dangerously low, while at the same time, disrupted paracrine signaling could allow glucagon to rise inappropriately when blood sugar is already too high. In people with diabetes, this paradoxical behavior of glucagon makes blood sugar management harder in both directions.
Somatostatin as the Islet’s Brake Pedal
Delta cells make up a relatively small fraction of islet cells, but somatostatin punches above its weight. It exerts a steady inhibitory influence on both insulin and glucagon secretion, keeping both hormones in check under resting conditions.3PubMed Central. Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function When a meal triggers the parasympathetic nervous system (the “rest and digest” branch), part of the resulting surge in insulin may come from releasing the brake that somatostatin normally applies. Delta-cell somatostatin is also involved in suppressing glucagon after a nutrient load, which helps prevent blood sugar from rising higher than it needs to.
Somatostatin’s reach within the islet is direct: it can inhibit both alpha and beta cells through specific receptors on their surfaces.7PubMed Central. Somatostatin Receptors Shape Insulin and Glucagon Output within the Pancreatic Islet through Direct and Paracrine Effects This makes the delta cell a central node in the islet’s internal communication network, even though it is often overlooked in favor of its flashier neighbors.
Signals From Outside the Islet
Islet cells do not operate in isolation. They receive instructions from at least two major external systems: the gut and the autonomic nervous system.
The Incretin Effect
You may have noticed that swallowing glucose produces a bigger insulin response than injecting the same amount directly into the bloodstream. That amplification is called the incretin effect, and it is driven largely by two gut hormones: GLP-1 and GIP. Both are released by cells in the intestinal lining when food arrives, and both bind to receptors on beta cells that ramp up insulin secretion in a glucose-dependent manner.8PubMed. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation The glucose-dependent part is important: incretins amplify the insulin signal only when blood sugar is already elevated, which limits the risk of dangerous lows. This safety feature is one reason drugs modeled on GLP-1, such as semaglutide and tirzepatide, have become central to modern diabetes treatment and, more recently, weight management.
Nerve Signals
The parasympathetic and sympathetic branches of the autonomic nervous system both reach the pancreas, but they pull in opposite directions. Parasympathetic activation stimulates insulin secretion, while sympathetic activation inhibits it.9PubMed. Autonomic regulation of islet hormone secretion–implications for health and disease This makes intuitive sense: the “fight or flight” response needs circulating glucose for muscles, so dialing down insulin keeps blood sugar available.
Here is where the human-versus-mouse difference matters again. In mice, autonomic nerve fibers make direct contact with endocrine cells throughout the islet. In humans, far fewer nerve fibers actually touch endocrine cells. Instead, sympathetic fibers in human islets preferentially innervate smooth muscle cells of blood vessels within the islet, suggesting that the nervous system may regulate human islet function partly by controlling local blood flow rather than by directly stimulating each cell.10PubMed Central. Innervation patterns of autonomic axons in the human endocrine pancreas This is a meaningful distinction that makes it risky to assume mouse neural-regulation data translate cleanly to people.
Fatty Acids and Other Non-Glucose Nutrients
Glucose is the star of islet physiology, but it is not the only nutrient beta cells respond to. Long-chain fatty acids amplify insulin secretion on top of whatever glucose is already doing, and a key player in this process is a receptor called GPR40 on the beta-cell surface.11PubMed. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40 In mouse experiments, knocking out GPR40 cut the insulin response to fatty acids roughly in half, while the response to glucose alone remained normal.12PubMed Central. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo So fatty acids use at least two routes to boost insulin: one through GPR40 and one through other pathways that researchers are still sorting out.
The fatty-acid story has a dark side. Short-term fatty acid exposure boosts insulin secretion, but chronic exposure to high levels of fatty acids and glucose together can damage beta cells, a process sometimes called glucolipotoxicity. This combination overwhelms the cell’s internal stress-management systems and can ultimately lead to beta-cell dysfunction and death, a pathway that contributes to the progression of type 2 diabetes.13PubMed Central. Guards and culprits in the endoplasmic reticulum: glucolipotoxicity and β-cell failure in type II diabetes
How Beta Cells Coordinate With Each Other
A single beta cell acting alone would produce erratic spurts of insulin. What keeps secretion organized is electrical coupling between neighboring beta cells through tiny protein tunnels called gap junctions, made of a protein called connexin 36. These junctions allow ions and small signaling molecules to pass between cells, synchronizing their electrical activity so that calcium rises in a coordinated wave across the islet.14PubMed Central. Intrinsic islet heterogeneity and gap junction coupling determine spatiotemporal Ca²⁺ wave dynamics That coordinated calcium wave is what drives the pulsatile release of insulin, the rhythmic on-off pattern that the body’s tissues respond to most efficiently.
When connexin 36 is removed experimentally, beta cells lose their synchronization. Calcium oscillations become chaotic, and basal insulin release increases while the sharp, glucose-triggered pulses flatten out.15PubMed. Loss of connexin36 channels alters beta-cell coupling, islet synchronization of glucose-induced Ca2+ and insulin oscillations, and basal insulin release This disrupted pattern appears in prediabetic states as well. Studies in prediabetic mice show that gap-junction coupling deteriorates as metabolic health worsens, and that caloric restriction can partially recover it.16PubMed Central. Caloric restriction recovers impaired β-cell-β-cell gap junction coupling, calcium oscillation coordination, and insulin secretion in prediabetic mice The implication is that the health of these tiny cell-to-cell connections may be an early indicator of whether the islet’s insulin machinery is starting to break down.
The Islet’s Internal Clock
Beta cells have their own circadian clock, and it directly shapes how much insulin they secrete at different times of day. In mouse islets, disrupting a core clock gene called BMAL1 flattened the normal daily rhythm of insulin release and altered the expression of genes involved in insulin processing and secretion.17PubMed Central. Pancreatic β cell enhancers regulate rhythmic transcription of genes controlling insulin secretion This means the beta cell is not just reacting to glucose in the moment; it is also anticipating when glucose is likely to show up based on the body’s internal schedule.
The practical fallout of this is relevant to anyone who works night shifts or has chronically disrupted sleep. If the islet’s clock is out of sync with actual meal timing, the insulin response can be mistimed, contributing to glucose intolerance. Epidemiological research consistently links shift work and chronic sleep disruption to higher diabetes risk, and the islet clock is one plausible piece of that puzzle.
What Goes Wrong in Diabetes
Both major forms of diabetes involve islet dysfunction, but by very different routes.
Type 1 Diabetes
In type 1 diabetes, the immune system’s T cells attack and destroy beta cells.18PubMed Central. T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes The hallmark of this process is insulitis, an inflammatory infiltration of immune cells in and around the islets.19PubMed Central. Insulitis in the pathogenesis of type 1 diabetes By the time symptoms appear, a substantial portion of beta-cell mass is already gone. Because alpha, delta, and other islet cells are largely spared, people with type 1 diabetes still produce glucagon and somatostatin, but the loss of insulin creates the defining metabolic crisis.
Type 2 Diabetes
Type 2 diabetes involves a slower, more insidious process. The tissues of the body become resistant to insulin, forcing beta cells to work harder and produce more. Over time, the chronic overload, especially in the setting of elevated glucose and fatty acids, stresses the internal machinery of the beta cell and can trigger cell death.13PubMed Central. Guards and culprits in the endoplasmic reticulum: glucolipotoxicity and β-cell failure in type II diabetes Alpha-cell function also goes awry: glucagon secretion often fails to drop after meals and fails to rise adequately during hypoglycemia, worsening blood sugar swings in both directions.
Islet Transplantation and Its Obstacles
The logic of islet transplantation is straightforward: if someone has lost their beta cells, replace them. Islets are isolated from a donor pancreas and infused into the recipient’s liver through the portal vein. The approach can work, but a major hurdle kicks in almost immediately. When transplanted islets contact blood, a cascade of inflammation and clotting called the instant blood-mediated inflammatory reaction (IBMIR) destroys a significant fraction of the transplanted cells within hours.20PubMed Central. α-1 Antitrypsin Enhances Islet Engraftment by Suppression of Instant Blood-Mediated Inflammatory Reaction This reaction occurs even in autologous transplants, where the islets come from the patient’s own pancreas, ruling out a purely immune-rejection explanation.21PubMed. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation
Because of IBMIR, multiple donor pancreases are often needed to achieve insulin independence in a single recipient, and long-term graft survival remains limited. Researchers are testing various strategies to blunt the inflammatory reaction, including anti-inflammatory proteins and physical barriers that shield the transplanted cells from blood contact.
Stem Cells and the Future of Beta-Cell Replacement
Donor organ scarcity has pushed the field toward growing beta cells from stem cells. Induced pluripotent stem cells can be coaxed into becoming insulin-producing cells in the lab, offering a theoretically unlimited supply.22PubMed Central. Stem Cell-Derived Beta-Cell Therapies: Encapsulation Advances and Immunological Hurdles in Diabetes Treatment The next challenge is keeping these cells alive once implanted. Encapsulation, in which stem-cell-derived beta cells are placed inside a protective device or material before transplantation, aims to shield the cells from immune attack while still allowing glucose and insulin to pass through.23PubMed. Encapsulation of stem-cell derived β-cells: A promising approach for the treatment for type 1 diabetes mellitus
Early clinical results are encouraging. In a trial of patients with type 1 diabetes, encapsulated stem-cell-derived beta cells implanted via a retrievable device established enough function to improve glucose control.24Nature Biotechnology. Encapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes The devices are designed to be removable, which adds a safety margin: if something goes wrong, the implant can be taken out. Immune rejection remains the biggest unsolved problem. Even with encapsulation, the body’s immune system finds ways to wall off the devices with scar tissue, gradually choking off the nutrient supply to the cells inside.
Seeing Islets in Living People
One of the biggest limitations in diabetes research is that you cannot easily measure how many functioning beta cells a person has while they are still alive. Blood tests for insulin and C-peptide give indirect clues, but they reflect what the remaining beta cells are doing, not how many are left. Positron emission tomography (PET) imaging using tracers that bind to beta cells is being developed as a way to visualize beta-cell mass directly.25PubMed Central. The Current State of Beta-Cell-Mass PET Imaging for Diabetes Research and Therapies A reliable imaging technique would transform both research and clinical care. It could help predict who is heading toward diabetes before symptoms start, track how well a transplant or regenerative therapy is working, and distinguish between people who have lost beta-cell mass and those whose beta cells are present but underperforming.
The challenge is finding a tracer that binds specifically to beta cells and not to the surrounding exocrine tissue, which makes up the vast majority of the pancreas. Several candidate tracers have been tested, but none has yet achieved the sensitivity and specificity needed for routine clinical use. The field considers this one of the most important unsolved technical problems in diabetes research.
From Pancreatic Extract to Precision Therapy
The islets’ connection to diabetes treatment goes back more than a century. In 1921, Frederick Banting and Charles Best, working in a lab at the University of Toronto, produced a pancreatic extract that lowered blood sugar in dogs whose pancreases had been removed. Their initial approach involved ligating the pancreatic ducts to destroy the enzyme-producing tissue while leaving the islets intact, then extracting the active substance. They later developed a method using whole beef pancreas, and the resulting extract proved effective in treating humans with diabetes.26PubMed. Insulin: discovery and controversy Earlier researchers had prepared similar extracts that lowered blood sugar in animals, but toxic impurities had prevented human use. The Toronto team’s contribution was not the concept but the purification.
A century later, researchers are still working on the same fundamental problem the discovery of insulin addressed: how to restore or replace the hormone output of damaged islets. The tools have changed from beef pancreas extracts to gene-edited stem cells and bioengineered encapsulation devices, but the target remains those same small clusters of cells that Paul Langerhans first described in 1869 as peculiar spots within the pancreatic tissue.